# A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

> **NCT07365319** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Eikon Therapeutics** · enrollment: 750 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer (Squamous or Non Squamous)
- Stage 4 NSCLC

## Interventions

- **DRUG:** EIK1001
- **DRUG:** Pembrolizumab (KEYTRUDA®)
- **DRUG:** Placebo
- **DRUG:** Paclitaxel + Carboplatin
- **DRUG:** Nab-paclitaxel + Carboplatin
- **DRUG:** Pemetrexed + Cisplatin /Carboplatin

## Key facts

- **NCT ID:** NCT07365319
- **Lead sponsor:** Eikon Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-18
- **Primary completion:** 2035-12-31
- **Final completion:** 2040-12-31
- **Target enrollment:** 750 (ESTIMATED)
- **Last updated:** 2026-01-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07365319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07365319, "A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07365319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*